SuperworthProMIS Neurosciences EPS PMN
Diluted earnings per share by quarter and over the last twelve months, from 2021.
- Last 12 months, to Jun 30, 2026
- −$12.69
- Latest quarter, Q2 FY26
- −$1.28
- Fiscal year 2025
- −$22.68
ProMIS Neurosciences' earnings per share was −$12.69 over the twelve months to Jun 30, 2026.
In its latest quarter, Q2 FY26, it was −$1.28.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | −$22.68 | n/a |
| FY2024 | −$0.50 | −115% |
| FY2023 | $3.25 | −93% |
| FY2022 | $48.25 | n/a |
| FY2021 | −$30.25 | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | −$1.28 | n/a | −$12.69 | |
| Q1 FY26 | −$1.26 | n/a | −$18.67 | |
| Q4 FY25 | −$4.15 | n/a | −$22.68 | |
| Q3 FY25 | −$6.00 | −177% | −$18.78 | |
| Q2 FY25 | −$7.26 | n/a | −$5.03 | |
| Q1 FY25 | −$5.27 | n/a | −$1.02 | |
| Q4 FY24 | −$0.25 | −101% | −$0.50 | |
| Q3 FY24 | $7.75 | n/a | $29.00 | |
| Q2 FY24 | −$3.25 | n/a | $16.50 | |
| Q1 FY24 | −$4.75 | n/a | $13.00 | |
| Q4 FY23 | $29.25 | −66% | $3.25 | |
| Q3 FY23 | −$4.75 | n/a | $59.75 |
Against its peers
Companies in Drug Manufacturers - General nearest ProMIS Neurosciences' size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| PMNProMIS Neurosciences | −$12.69 | |
| LFVNLifevantage | $0.40 | −46% a year |
| SPROSpero Therapeutics | $0.11 | |
| ATNMActinium Pharmaceuticals | $0.36 | |
| NATRNatures Sunshine Products | $1.01 | +36% a year |
| ARVNArvinas | $0.16 | |
| PBYIPuma Biotechnology | $0.52 | −47% a year |
| IRWDIronwood Pharmaceuticals | $0.77 | |
| ZVRAZevra Therapeutics | $0.93 | |
| CRMDCorMedix | $2.13 | +184% a year |
| COLLCollegium Pharmaceutical | $1.24 | +19% a year |
| Peer median | $0.65 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on ProMIS Neurosciences
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.